The intracellular genistein metabolite 5,7,3′,4′-tetrahydroxyisoflavone mediates G2-M cell cycle arrest in cancer cells via modulation of the p38 signaling pathway

Free Radical Biology and Medicine

Volumn 41, Issue 8, 2006, Pages 1225-1239

  Nguyen, Dominique T ^a   Hernandez Montes, Eva ^b   Vauzour, David ^b   Schönthal, Axel H ^d   Rice Evans, Catherine ^c   Cadenas, Enrique ^a   Spencer, Jeremy P E ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF READING   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast cancer; Cell signaling; Genistein; Isoflavone; MAP kinase; Metabolism

Indexed keywords

5,7,3',4' TETRAHYDROXYISOFLAVONE; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYTOCHROME P450; GENISTEIN; ISOFLAVONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; SERINE; THREONINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE;

BREAST; BREAST NEOPLASMS; CDC2 PROTEIN KINASE; CELL CYCLE; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CIMETIDINE; EPITHELIAL CELLS; FEMALE; G2 PHASE; GENISTEIN; HUMANS; MODELS, BIOLOGICAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 33749247249     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.06.026     Document Type: Article

References (55)

1. Bradlow H.L., and Sepkovic D.W. Diet and breast cancer. Ann. N. Y. Acad. Sci. 963 (2002) 247-267
2. Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res. Treat. 46 (1997) 169-179
3. Lamartiniere C.A. Protection against breast cancer with genistein: a component of soy. Am. J. Clin. Nutr. 71 (2000) 1705S-1707S
4. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J. Nutr. 125 (1995) 777S-783S
5. Lambert J.D., Hong J., Yang G.Y., Liao J., and Yang C.S. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am. J. Clin. Nutr. 81 (2005) 284S-291S
6. Magee P.J., and Rowland I.R. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br. J. Nutr. 91 (2004) 513-531
7. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., and Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262 (1987) 5592-5595
8. Constantinou A., Mehta R., Runyan C., Rao K., Vaughan A., and Moon R. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J. Nat. Prod. 58 (1995) 217-225
9. Fotsis T., Pepper M., Adlercreutz H., Hase T., Montesano R., and Schweigerer L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J. Nutr. 125 (1995) 790S-797S
10. Dang Z.C., Audinot V., Papapoulos S.E., Boutin J.A., and Lowik C.W. Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J. Biol. Chem. 278 (2003) 962-967
11. Zhou Y., and Lee A.S. Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. J. Natl. Cancer Inst. 90 (1998) 381-388
12. Chang H.C., Churchwell M.I., Delclos K.B., Newbold R.R., and Doerge D.R. Mass spectrometric determination of genistein tissue distribution in diet-exposed Sprague-Dawley rats. J. Nutr. 130 (2000) 1963-1970
13. Kulling S.E., Lehmann L., and Metzler M. Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 777 (2002) 211-218
14. Kulling S.E., Honig D.M., and Metzler M. Oxidative metabolism of the soy isoflavones daidzein and genistein in humans in vitro and in vivo. J. Agric. Food Chem. 49 (2001) 3024-3033
15. Kulling S.E., Honig D.M., Simat T.J., and Metzler M. Oxidative in vitro metabolism of the soy phytoestrogens daidzein and genistein. J. Agric. Food Chem. 48 (2000) 4963-4972
16. Roberts-Kirchhoff E.S., Crowley J.R., Hollenberg P.F., and Kim H. Metabolism of genistein by rat and human cytochrome P450s. Chem. Res. Toxicol. 12 (1999) 610-616
17. Doerge D.R., Chang H.C., Churchwell M.I., and Holder C.L. Analysis of soy isoflavone conjugation in vitro and in human blood using liquid chromatography-mass spectrometry. Drug Metab. Dispos. 28 (2000) 298-307
18. Peterson T.G., Coward L., Kirk M., Falany C.N., and Barnes S. The role of metabolism in mammary epithelial cell growth inhibition by the isoflavones genistein and biochanin A. Carcinogenesis 17 (1996) 1861-1869
19. Cappelletti V., Fioravanti L., Miodini P., and Di F.G. Genistein blocks breast cancer cells in the G(2)M phase of the cell cycle. J. Cell. Biochem. 79 (2000) 594-600
20. Constantinou A.I., Kamath N., and Murley J.S. Genistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cells. Eur. J. Cancer 34 (1998) 1927-1934
21. Casagrande F., and Darbon J.M. p21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp. Cell Res. 258 (2000) 101-108
22. Kuzumaki T., Kobayashi T., and Ishikawa K. Genistein induces p21(Cip1/WAF1) expression and blocks the G1 to S phase transition in mouse fibroblast and melanoma cells. Biochem. Biophys. Res. Commun. 251 (1998) 291-295
23. Frey R.S., Li J., and Singletary K.W. Effects of genistein on cell proliferation and cell cycle arrest in nonneoplastic human mammary epithelial cells: involvement of Cdc2, p21(waf/cip1), p27(kip1), and Cdc25C expression. Biochem. Pharmacol. 61 (2001) 979-989
24. Frey R.S., and Singletary K.W. Genistein activates p38 mitogen-activated protein kinase, inactivates ERK1/ERK2 and decreases Cdc25C expression in immortalized human mammary epithelial cells. J. Nutr. 133 (2003) 226-231
25. Schroeter H., Boyd C., Spencer J.P., Williams R.J., Cadenas E., and Rice-Evans C. MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide. Neurobiol. Aging 23 (2002) 861-880
26. Schroeter H., Spencer J.P., Rice-Evans C., and Williams R.J. Flavonoids protect neurons from oxidized low-density-lipoprotein-induced apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and caspase-3. Biochem. J. 358 (2001) 547-557
27. Spencer J.P.E., Rice-Evans C., and Williams R.J. Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. J. Biol. Chem. 278 (2003) 34783-34793
28. Chang T., Levine M., Bandiera S.M., and Bellward G.D. Selective inhibition of rat hepatic microsomal cytochrome P-450. I. Effect of the in vivo administration of cimetidine. J. Pharmacol. Exp. Ther. 260 (1992) 1441-1449
29. Spencer J.P.E., Kuhnle G.G., Williams R.J., and Rice-Evans C. Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. Biochem. J. 372 (2003) 173-181
30. Qiu X.B., Schonthal A.H., and Cadenas E. Anticancer quinones induce pRb-preventable G2/M cell cycle arrest and apoptosis. Free Radic. Biol. Med. 24 (1998) 848-854
31. Breinholt V.M., Rasmussen S.E., Brosen K., and Friedberg T.H. In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s. Pharmacol. Toxicol. 93 (2003) 14-22
32. Norbury C., and Nurse P. Animal cell cycles and their control. Annu. Rev. Biochem. 61 (1992) 441-470
33. Galaktionov K., Jessus C., and Beach D. Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev. 9 (1995) 1046-1058
34. Bulavin D.V., and Fornace Jr. A.J. p38 MAP kinase's emerging role as a tumor suppressor. Adv. Cancer Res. 92 (2004) 95-118
35. Garner A.P., Weston C.R., Todd D.E., Balmanno K., and Cook S.J. Delta MEKK3:ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G2 checkpoint. Oncogene 21 (2002) 8089-8104
36. Chao J.I., and Yang J.L. Opposite roles of ERK and p38 mitogen-activated protein kinases in cadmium-induced genotoxicity and mitotic arrest. Chem. Res. Toxicol. 14 (2001) 1193-1202
37. Li J., Meyer A.N., and Donoghue D.J. Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation. Proc. Natl. Acad. Sci. USA 94 (1997) 502-507
38. Lee J.C., Kassis S., Kumar S., Badger A., and Adams J.L. p38 mitogen-activated protein kinase inhibitors-Mechanisms and therapeutic potentials. Pharmacol. Ther. 82 (1999) 389-397
39. Salti G.I., Grewal S., Mehta R.R., Das Gupta T.K., Boddie Jr. A.W., and Constantinou A.I. Genistein induces apoptosis and topoisomerase II-mediated DNA breakage in colon cancer cells. Eur. J. Cancer 36 (2000) 796-802
40. Constantinou A.I., Mehta R.G., and Vaughan A. Inhibition of N-methyl-N-nitrosourea-induced mammary tumors in rats by the soybean isoflavones. Anticancer Res. 16 (1996) 3293-3298
41. Constantinou A., Kiguchi K., and Huberman E. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res. 50 (1990) 2618-2624
42. Messina M.J. Legumes and soybeans: overview of their nutritional profiles and health effects. Am. J. Clin. Nutr. 70 (1999) 439S-450S
43. Fritz W.A., Wang J., Eltoum I.E., and Lamartiniere C.A. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol. Cell. Endocrinol. 186 (2002) 89-99
44. Dalu A., Blaydes B.S., Bryant C.W., Latendresse J.R., Weis C.C., and Barry D.K. Estrogen receptor expression in the prostate of rats treated with dietary genistein. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 777 (2002) 249-260
45. Dalu A., Haskell J.F., Coward L., and Lamartiniere C.A. Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate. Prostate 37 (1998) 36-43
46. Guengerich F.P., Hosea N.A., Parikh A., Bell-Parikh L.C., Johnson W.W., Gillam E.M., and Shimada T. Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. Drug Metab. Dispos. 26 (1998) 1175-1178
47. Patterson L.H., and Murray G.I. Tumour cytochrome P450 and drug activation. Curr. Pharm. Des. 8 (2002) 1335-1347
48. Waxman D.J., Chen L., Hecht J.E., and Jounaidi Y. Cytochrome P450-based cancer gene therapy: recent advances and future prospects. Drug Metab. Rev. 31 (1999) 503-522
49. Jounaidi Y. Cytochrome P450-based gene therapy for cancer treatment: from concept to the clinic. Curr. Drug Metab. 3 (2002) 609-622
50. Kiriakidis S., Hogemeier O., Starcke S., Dombrowski F., Hahne J.C., Pepper M., Jha H.C., and Wernert N. Novel tempeh (fermented soyabean) isoflavones inhibit in vivo angiogenesis in the chicken chorioallantoic membrane assay. Br. J. Nutr. 93 (2005) 317-323
51. Monks T.J., and Lau S.S. The pharmacology and toxicology of polyphenolic-glutathione conjugates. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 229-255
52. Monks T.J., and Lau S.S. Biological reactivity of polyphenolic-glutathione conjugates. Chem. Res. Toxicol. 10 (1997) 1296-1313
53. Shimizu M., and Weinstein I.B. Modulation of signal transduction by tea catechins and related phytochemicals. Mutat. Res. 591 (2005) 147-160
54. Watanabe N., Broome M., and Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J. 14 (1995) 1878-1891
55. Kousidou O.C., Tzanakakis G.N., and Karamanos N.K. Effects of the natural isoflavonoid genistein on growth, signaling pathways and gene expression of matrix macromolecules by breast cancer cells. Mini. Rev. Med. Chem. 6 (2006) 331-337